Related Experiment Video

Updated: May 30, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab

M Stosic1, P De Jesus, J McCarthy

  • 1Baylor College of Medicine, Houston, TX 77054, USA. stosicmil@yahoo.com

Neurology
|July 22, 2011
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...